- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Large Health Insurers Plan to Make Cuts to Their Medicare Advantage Programs
Facing anticipated reductions in funding and regulatory changes under the health care reform law, several of the nation's largest health insurers have indicated plans to scale back their Medicare Advantage programs.
Facing anticipated reductions in funding and regulatory changes under the health care reform law, several of the nation's largest health insurers have indicated plans to scale back their Medicare Advantage programs.
Beginning in 2014, insurers' Medicare Advantage plans will be held to a minimum medical-loss ratio of 85% under the Patient Protection and Affordable Care Act. The reform law also calls for a $156 billion reduction in Medicare Advantage payments by 2022.
Those cuts, coupled with the 2% overall reduction in Medicare spending under the Budget Control Act of 2011 and potential further cuts resulting from ongoing budget negotiations in Congress, prompted senior executives at several leading health insurers to outline planned withdrawals from certain Medicare Advantage markets and narrowed Medicare benefit plan offerings during recent calls with securities analysts.
Read the full story here: http://bit.ly/14VoXwo
Source: Business Insurance
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
